Neptra Ear Drops Solution for Dogs – SPC change
Change to the information provided on adverse events in the Summary of Product Characteristics for Neptra Ear Drops Solution for Dogs.
Following monitoring of pharmacovigilance data, the Summary of Product Characteristics (SPC) for Neptra Ear Drops Solution for Dogs has been updated:
- The safety and efficacy of the veterinary medicinal product in cats has not been evaluated.
- Post-marketing surveillance shows that the use of the product in cats can be associated with neurological signs (including ataxia, Horner’s syndrome with protrusion of membrane nictitans, miosis, anisocoria), internal ear disorders (head tilt) and systemic signs (anorexia and lethargy).
- The use of the veterinary medicinal product in cats should therefore be avoided.
Any veterinary medicinal product which is authorised for marketing in the United Kingdom will have its Summary of Product Characteristics (SPC) available on our Product Information Database.
No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in either section Adverse events (3.6) or Adverse reactions (4.6).
All updates to SPCs other than template changes, are published in the medicine updates section of VMD Connect.